18 June 2013
Elan Advises Shareholders to Withdraw Any Acceptances of the Royalty Pharma Offer and Not to Tender Any Further Acceptances into This Lapsed Offer*| DUBLIN--(BUSINESS WIRE)--Jun. 18, 2013--
Elan Corporation, plc (NYSE: ELN) (Elan or the Company) today advises
Elan Shareholders to withdraw any acceptances of Royalty Pharma’s Offer
without delay and not to tender any further acceptances. Following the
outcome of the Elan EGM yesterday morning, and in accordance with the
terms of the Royalty Pharma Offer, the Royalty Pharma Offer has now
lapsed*.
Withdrawal of acceptances of the Royalty P... |
|
17 June 2013
Elan Announces Results of EGM| Share Repurchase Resolution Approved
Royalty Pharma Hostile Bid Lapses in Accordance with Its Terms
DUBLIN--(BUSINESS WIRE)--Jun. 17, 2013--
Elan Corporation, plc (NYSE:ELN) (Elan or the Company) announces that,
at its Extraordinary General Meeting held earlier today, shareholders
approved the Share Repurchase Program.
Shareholders did not approve the Theravance Transaction, the AOP
Transaction or the ELND005 ... |
|
14 June 2013
Elan To Proceed with Formal Sale Process| Elan Board authorizes formal sale process to commence
Board and management are aligned in maximizing the full value
potential of the business on behalf of Elan’s shareholders
Royalty Pharma is invited to participate in the formal sale process
DUBLIN--(BUSINESS WIRE)--Jun. 14, 2013--
Elan Corporation, plc (NYSE:ELN) (Elan or the Company) today announced
that it is proceeding with a formal sale process in l... |
|
11 June 2013
Elan Issues Open Letter Urging Shareholders to Vote Today IN FAVOR of All Four EGM Resolutions| DUBLIN--(BUSINESS WIRE)--Jun. 11, 2013--
Elan Corporation, plc (NYSE:ELN) (Elan or the Company) today issued a
letter urging shareholders to protect the value of their investment in
Elan by rejecting Royalty Pharma’s grossly inadequate offer to acquire
Elan and by voting FOR all four resolutions in connection with Elan’s
fast approaching Extraordinary General Meeting (EGM).
The full text of the letter is below:
URGENT: PROTECT YOUR... |
|
10 June 2013
Elan Withdraws Lawsuit – Royalty Pharma Made Significant Additional Disclosure| DUBLIN--(BUSINESS WIRE)--Jun. 10, 2013--
Elan Corporation, plc (NYSE: ELN) (Elan) today announced a successful
result in the litigation Elan commenced one week ago in the United
States District Court for the Southern District of New York (the
“Court”) to compel corrective disclosure in Royalty Pharma’s tender
offer documents. Elan is withdrawing its complaint before the Court
because Royalty Pharma, in response to Elan’s complaint, was forced to
r... |
|
10 June 2013
Elan Board Of Directors Unanimously And Without Reservation Rejects Royalty Pharma's Revised Tender Offer| Royalty Pharma (Echo Pharma) revised offer (cash and CVR) continues
to grossly undervalue TYSABRI
Contingent Value Rights (CVR) fall substantially short of TYSABRI’s
value in the event CVR payment triggers are achieved
EGM on June 17, 2013 enables shareholders to vote on previously
announced strategic transactions
Board unanimous in recommending these four transactions
T... |
|
07 June 2013
Elan's Response to Royalty Pharma Announcement| DUBLIN--(BUSINESS WIRE)--Jun. 7, 2013--
The Board of Elan Corporation, plc (NYSE:ELN) (Elan) notes today’s
announcement regarding the revised offer by Echo Pharma Acquisition
Limited (“Royalty Pharma”) to acquire Elan's shares under Rule 2.5 of
the Irish Takeover Rules.
The Board of Elan will, as before, in line with its obligations under
Irish Takeover law, assess the Royalty Pharma announcement and will
advise its shareholders accordingl... |
|
06 June 2013
Elan's Response to Irish Takeover Panel Rulings| ROYALTY PHARMA MUST LAPSE OFFER IF ANY OF THE EGM RESOLUTIONS ARE
PASSED
ROYALTY PHARMA PROXY STATEMENT BREACHED TAKEOVER RULES
DUBLIN--(BUSINESS WIRE)--Jun. 6, 2013--
Elan Corporation, plc (NYSE: ELN) (Elan) notes today's ruling by the
Irish Takeover Panel (the "Panel") that Royalty Pharma must lapse its
offer for Elan if any of the resolutions being put to Elan's EGM on June
17, 2013 are passed.
... |
|
05 June 2013
Elan Injunction; Royalty Pharma Issues Grossly Misleading Statement; Elan to Pursue Royalty Pharma's Misrepresentations and Lack of Disclosure with Relevant Authorities; US District Court Issues Temporary Restraining Order| DUBLIN--(BUSINESS WIRE)--Jun. 5, 2013--
Elan Corporation, plc (NYSE: ELN) (Elan) announces that earlier today
Royalty Pharma issued a grossly misleading statement regarding the
outcome yesterday of Elan's Irish High Court proceedings. On June 3,
2013, the Court prohibited Royalty Pharma from disseminating a Proxy
Statement which, Elan believes, breached the Irish Takeover Rules.
Yesterday, Royalty Pharma confirmed in Court in Dublin that it would not
... |
|
04 June 2013
Elan Announces Outcome of Irish High Court Injunction| ROYALTY PHARMA TO REFRAIN FROM PUBLISHING ITS PROXY STATEMENT TO
SHAREHOLDERS
IRISH TAKEOVER PANEL TO REVIEW ROYALTY PHARMA'S COMPLIANCE WITH
RULES
DUBLIN--(BUSINESS WIRE)--Jun. 4, 2013--
Elan Corporation, plc (NYSE: ELN) (Elan) confirms that Royalty Pharma
has this afternoon (Irish time) agreed not to further disseminate its
proxy statement, which the Irish High Court on June 3, 2013 restrained
Royalty Pha... |
|
03 June 2013
Elan Awarded Injunction against Royalty Pharma in Ireland| Elan Files Temporary Restraining Order against Royalty Pharma in US
DUBLIN--(BUSINESS WIRE)--Jun. 3, 2013--
Elan Corporation, plc (NYSE: ELN) this afternoon (Irish time) received
injunctive relief from the Irish High Court restraining Echo Pharma
Acquisition Limited (Royalty Pharma's bid vehicle) from distributing to
Elan's shareholders a proxy statement filed with the United States
Securities and Exchange Commission at 10.18 p.m. (Irish time) on Fri... |
|
03 June 2013
Elan Issues Response Document Further Detailing Inadequacy of Royalty Pharma's Revised Offer| Royalty Pharma's Revised Offer Grossly Undervalues Elan's Tysabri and
Cash Value alone
Royalty Pharma's Revised Offer - Misleading and Simplistic1
DUBLIN--(BUSINESS WIRE)--Jun. 3, 2013--
Elan Corporation, plc (NYSE: ELN) today issued a formal response
document in respect of the Echo Pharma Acquisition Limited (Royalty
Pharma) revised offer made on May 23, 2013. The response document is
available on Elan’s website at www.elan.co... |
|
30 May 2013
Elan to Present at the Jefferies 2013 Global Healthcare Conference| DUBLIN--(BUSINESS WIRE)--May. 30, 2013--
Elan Corporation, plc (NYSE: ELN) today announced that it will present
at the Jefferies 2013 Global Healthcare Conference on Wednesday, June 5,
2013 at 9:30 a.m. Eastern Time (ET), 2:30 p.m. British Summer Time (BST).
Interested parties may access a live audio webcast of the presentation
by visiting the Investor Relations section of the Elan website at http://www.elan.com,
then clicking on the event icon. ... |
|
29 May 2013
Elan Provides Shareholders with Categorical View on Value| The underlying value of Tysabri is $11.85 per share1.
The upside is $17.15 per share2
Additionally, the value of the cash is $3.65 per share3
In total, the aggregate value of the Tysabri asset, pre-deduction
of operating expenses, together with cash is $15.50 to $20.804
5
Royalty Pharma’s $12.50 bid currently undervalues these assets by
up to $4.3 billion6
Tende... |
|
27 May 2013
Elan Announces Publication of Notice of Extraordinary General Meeting| DUBLIN--(BUSINESS WIRE)--May. 27, 2013--
Elan Corporation, plc (NYSE: K) (“Elan” or the “Company”) today
publishes the Notice (including details of the transactions) of an
Extraordinary General Meeting of the Company (the “EGM”). The Notice of
the EGM together with a Form of Proxy will be issued to shareholders
today. The EGM will be held at The O’Callaghan Davenport Hotel, 8/10
Merrion Street Lower, Dublin 2, Ireland on Monday, June 17, 2013 at
1... |
|
23 May 2013
Elan Announces Pricing of US$850 Million in Aggregate Principal Amount of Senior Notes Due 2021| DUBLIN--(BUSINESS WIRE)--May. 23, 2013--
Elan Corporation, plc (“Elan”) (NYSE: ELN) today announced the pricing
of the offering of US$850 million aggregate principal amount of 6.250%
Senior Notes due 2021 (the “Notes”) by its wholly-owned subsidiaries,
Elan Finance public limited company and Elan Finance Corp. The Notes
will be issued at par. The offering is expected to close on May 31,
2013, subject to customary closing conditions. The Notes will be ful... |
|
23 May 2013
Elan Corporation, plc' s Board of Directors Unanimously Reject Royalty Pharma' s Revised Tender Offer| DUBLIN--(BUSINESS WIRE)--May. 23, 2013--
Elan Corporation, plc (NYSE: ELN) (Elan) today announced that its Board
of Directors, after careful review and consideration and with the
assistance of its executive management team as well as outside financial
and legal advisors, has determined that privately held investment firm
Royalty Pharma's revised offer (“Royalty Pharma Offer") announced on
Monday May 20, 2013 to acquire all of Elan's shares for $12.50 per... |
|
20 May 2013
Elan Announces Transactions: Decisively Transforming the Company| Proposed Transactions offer shareholders highly unique investment
and asset proposition
Acquisition of AOP Orphan – a private, orphan disease company
headquartered in Vienna, Austria
Acquires 48% of Newbridge Pharmaceuticals – a private Africa,
Middle East & Turkey (AfMET) company, headquartered in Dubai, UAE
AOP & Newbridge together reach 20%+ of the world’s growing
population ... |
|
20 May 2013
Elan Announces Proposed Offering of US$800.0 Million in Aggregate Principal Amount of Senior Notes Due 2021| DUBLIN--(BUSINESS WIRE)--May. 20, 2013--
Elan Corporation, plc (“Elan”) (NYSE: ELN) today announced that its
wholly-owned subsidiaries, Elan Finance public limited company (“Elan
Finance”) and Elan Finance Corp. (“Elan Corp.” and together with Elan
Finance, the “Issuers”), intend to offer, subject to market conditions,
US$800.0 million in aggregate principal amount of Senior Notes due 2021
(the “Notes”). The Notes will be fully and unconditionally guaran... |
|
20 May 2013
Elan's Response to Royalty Pharma Announcement| DUBLIN--(BUSINESS WIRE)--May. 20, 2013--
The Board of Elan Corporation, plc (NYSE : ELN) (Elan) notes today’s
announcement regarding the revised offer by Echo Pharma Acquisition
Limited (“Royalty Pharma”) to acquire Elan's shares under Rule 2.5 of
the Irish Takeover Rules.
The Board of Elan will, as before, in line with its obligations under
Irish Takeover law, assess the Royalty Pharma announcement and will
advise its shareholders accordi... |
|
15 May 2013
Elan Announces Publication of Response Document| DUBLIN--(BUSINESS WIRE)--May. 15, 2013--
Elan Corporation, plc (NYSE : ELN) (Elan) today announces publication of
a response document in respect of the Echo Pharma Acquisition Limited
(Royalty Pharma) offer made on May 2, 2013.
The response document is published in accordance with Rules 25 and 30.3
of the Irish Takeover Rules and the United States tender offer rules. As
previously advised, the Board of Elan has unanimously, and without
res... |
|
13 May 2013
Elan Provides Additional Commentary on Elan/Theravance Royalty Participation Agreement| Agreement enables science and therapeutic diversification of the
Elan business portfolio
Transaction provides investment in one approved and three
additional respiratory programs
Transaction expected to be earnings accretive (pre-amortisation)
from 2014
Transaction fully leverages Elan’s unique business and financial
structure
Anticipate single digit tax rate on... |
|
13 May 2013
Theravance and Elan Enter Into a $1.0 Billion Royalty Participation Agreement| Theravance to receive $1.0 billion upfront payment upon closing
Elan to receive a 21% participation interest in potential future
royalty payments associated with four respiratory programs
SOUTH SAN FRANCISCO, Calif. & DUBLIN--(BUSINESS WIRE)--May. 13, 2013--
Theravance, Inc. (NASDAQ: THRX) and Elan Corporation, plc (NYSE: ELN)
today announced that they have entered into a royalty participation
agreement wherein Elan will purchase a partic... |
|
25 April 2013
Elan Announces Publication of Notice of 2013 Annual General Meeting & Directors' Retirement| DUBLIN--(BUSINESS WIRE)--Apr. 25, 2013--
Elan Corporation, plc (NYSE: ELN) (“Elan” or the “Company”) today
publishes the Notice of the 2013 Annual General Meeting of the Company
(the “AGM”). The Notice of AGM together with a Form of Proxy has been
issued to shareholders. The 2013 AGM will be held at The Shelbourne
Hotel, 27 St. Stephen’s Green, Dublin 2, Ireland on Thursday, 30 May
2013 at 10.00 a.m. Details of the business to be transacted at the AGM
... |
|
24 April 2013
Elan Reports First Quarter 2013 Financial Results| DUBLIN--(BUSINESS WIRE)--Apr. 24, 2013--
Elan Corporation, plc today reported its first quarter 2013 financial
results.
Mr. Kelly Martin, CEO, said, “Activity in the first quarter of 2013 was
primarily strategic and consistent with the principles that have guided
us for nearly a decade. Those principles include reducing uncontrollable
risk where possible; taking calculated risk where the probabilities look
favorable; diversifying across sc... |
|
22 April 2013
Elan Corporation, plc' s Board of Directors Unanimously Reject Royalty Pharma's Unsolicited Tender Offer| DUBLIN--(BUSINESS WIRE)--Apr. 22, 2013--
Elan Corporation, plc (NYSE: ELN) (Elan) today announced that its Board
of Directors, after careful review and consideration and with the
assistance of its executive management team as well as outside financial
and legal advisors, has determined that privately held investment firm
Royalty Pharma's offer, through its shell subsidiary Echo Pharma
Acquisition Limited, to acquire all of the shares of Elan for $11.25 o... |
|
18 April 2013
Elan Announces Final Results of its Tender Offer| DUBLIN--(BUSINESS WIRE)--Apr. 18, 2013--
Elan Corporation, plc (NYSE:ELN) (Elan) today announced the final
results of its modified Dutch auction Tender Offer, to purchase its
Ordinary Shares, including Ordinary Shares represented by American
Depositary Shares (Shares), up to a maximum aggregate cost of US$1.0
billion, which closed at 8:00 a.m., Irish time, on April 18, 2013.
Key results of the Tender Offer
The key results of the Te... |
|
15 April 2013
Elan's Response to Royalty Pharma Announcement| DUBLIN--(BUSINESS WIRE)--Apr. 15, 2013--
The Board of Elan Corporation, plc (NYSE : ELN) (Elan) notes this
morning’s announcement regarding the offer by Echo Pharma Acquisition
Limited (“Royalty Pharma”) to acquire Elan's shares under Rule 2.5 of
the Irish Takeover Rules.
We have said consistently that we would give consideration to any formal
proposal by any party for Elan. The Board of Elan will, in line with its
obligations under Irish ... |
|
12 April 2013
Elan EGM Resolution Passed with over 99% Approval| DUBLIN--(BUSINESS WIRE)--Apr. 12, 2013--
Elan Corporation, plc (NYSE: ELN) announces that, at an Extraordinary
General Meeting (EGM) held earlier today, the sole ordinary resolution
to approve the Tender Offer to purchase Ordinary Shares (including
Ordinary Shares represented by American Depositary Shares) was
overwhelmingly passed with over 99% of the shares voted in favor of the
resolution. The full text of the resolution was included in the notice
... |
|
10 April 2013
Elan Announces Webcast of First Quarter 2013 Financial Results| DUBLIN--(BUSINESS WIRE)--Apr. 10, 2013--
Elan Corporation, plc (NYSE: ELN) announced today that it will host a
conference call on Wednesday, April 24, 2013 at 8:30 a.m. Eastern Time
(ET), 1:30 p.m. British Summer Time (BST) with the investment community
to discuss Elan’s first quarter 2013 financial results, which will be
released before the European and U.S. financial markets open.
Live audio of the conference call will be simultaneously broadca... |
|
03 April 2013
Elan Welcomes Irish Takeover Panel Statement| DUBLIN--(BUSINESS WIRE)--Apr. 3, 2013--
The Board of Elan Corporation, plc (NYSE:ELN) (the Company) welcomes
this morning's imposition by the Irish Takeover Panel of an expected May
10, 2013 deadline on Royalty Management LLC (Royalty Pharma) (following
their original indication of interest announcement of February 25, 2013)
by which Royalty Pharma must either announce an offer for Elan under
Rule 2.5 of the Irish Takeover Rules or announce that it will ... |
|
02 April 2013
Elan Announces Redemption of Its Senior Notes Due 2019| DUBLIN--(BUSINESS WIRE)--Apr. 2, 2013--
Elan Corporation, plc (NYSE:ELN) (the Company) announced today that it
has issued an irrevocable Notice of Redemption to redeem all of the $600
million in aggregate principal amount of outstanding 6.25% Senior Notes
due 2019 (the “Notes”) of its wholly owned subsidiaries, Elan Finance
public limited company and Elan Finance Corp. The redemption is expected
to occur on May 2, 2013.
The Notice of Redem... |
|
02 April 2013
Elan Announces Closing of TYSABRI® Collaboration Transaction with Biogen Idec| DUBLIN--(BUSINESS WIRE)--Apr. 2, 2013--
Elan Corporation, plc (NYSE:ELN) is pleased to announce the closing
today of the TYSABRI® (natalizumab) Collaboration Transaction
with Biogen Idec. The agreement was announced on February 6, 2013.
Under the terms of the agreement, Elan has received $3.25 billion in
cash and will receive double digit tiered royalty payments, on all
indications, for the life of the complete TYSABRI asset. For the first
... |
|
18 March 2013
New TYSABRI Data Reaffirm Substantial Efficacy in Treatment of People with MS and Demonstrate Stability of Anti-JCV Antibody Status|
– Continued Research into Risk Stratification and PML Early Detection
Provides Additional Insights for Physicians –
WESTON, Mass.--(BUSINESS WIRE)--Mar. 18, 2013--
Biogen Idec (NASDAQ: BIIB) and Elan
Corporation, plc (NYSE: ELN) announced results from several studies of
TYSABRI® (natalizumab) that demonstrate its efficacy
compared to other multiple sclerosis (MS) treatments, provide additional
data supporting anti-JC virus (JCV) antibo... |
|
12 March 2013
Elan Discloses Filing of Share Repurchase Tender Offer Documentation| DUBLIN--(BUSINESS WIRE)--Mar. 12, 2013--
Elan Corporation, plc (NYSE:ELN) (the Company) today disclosed the
Tender Offer documentation for the Share Repurchase has been filed and
is available on the Company’s website at www.elan.com.
Consequent on the closing of the previously-announced Tysabri
Transaction, Elan will issue an irrevocable Notice of Redemption to
redeem all of the outstanding 6.25% Notes due 2019 at a redemption price
eq... |
|
08 March 2013
Elan Provides Update on Tysabri Transaction and $1bn Share Repurchase|
US and EU Regulatory Closing Conditions Satisfied
Dutch Auction Share Repurchase Process to Commence March 11, 2013
The Price Range will be $11.25 to $13.00
Shareholder Meeting to Approve Share Repurchase Set for April 12,
2013
DUBLIN--(BUSINESS WIRE)--Mar. 8, 2013--
Elan Corporation, plc (NYSE:ELN) (the Company) today provides an update
on the Tysabri Restructur... |
|
06 March 2013
Elan's Response to Royalty Pharma Statement of Today| DUBLIN--(BUSINESS WIRE)--Mar. 6, 2013--
The Board of Elan Corporation, plc (NYSE:ELN) (the Company) acknowledges
this morning's statement by Royalty Management, LLC (Royalty Pharma).
Elan’s position remains as outlined on February 25, 2013:
The “proposal” by Royalty Pharma remains an indication of interest, is
highly conditional and may or may not lead to an offer being made for
the entire issued share capital of the Company.
... |
|
04 March 2013
Elan Announces Further Unlocking of Value To Benefit Shareholders|
Unique Cash Dividend For Shareholders
Dividend Calculated As a Percentage of Tysabri Royalty Payments To
Elan
Initial Percentage To Be Paid to Shareholders is 20% of That Royalty
Establishes Direct Link Between Shareholders And Tysabri Cash Flow
Novel Construct Crystalizes Further Shareholder Benefit Post
Tysabri Restructuring
DUBLIN--(BUSINES... |
|
28 February 2013
Elan Announces the Appointment of Mr. John Given as General Counsel| DUBLIN--(BUSINESS WIRE)--Feb. 28, 2013--
Elan Corporation, plc (NYSE:ELN) today announced the appointment of Mr.
John Given as General Counsel with effect from 1 March, 2013. Mr. Given
will report to the CEO, serve as a member of Elan’s executive management
team as well as serve as advisor to the Chairman and the full Board. He
will be based in Elan’s Dublin headquarters office.
Mr. Given joins Elan from leading Irish law firm A&L Goodbod... |
|
25 February 2013
Elan's Response to Indication of Interest| DUBLIN--(BUSINESS WIRE)--Feb. 25, 2013--
The Board of Elan Corporation, plc (NYSE:ELN) (the Company) acknowledges
this morning's announcement by Royalty Management, LLC (Royalty Pharma)
regarding an indicative, conditional, proposal which may or may not lead
to an offer being made for the entire issued share capital of the
Company.
As previously announced, in anticipation of executing and closing the
recently announced Tysabri transact... |
|
22 February 2013
Elan Provides Update Post Restructuring Announcement of Tysabri Collaboration|
Post-Closing Deployment Plan For Upfront Payment Of $3.25 Billion
Tax Efficient Transaction Enables Substantially All of Proceeds To
Be Realized and Utilized
Deployment Of Capital To Diversify Business and Strengthen Capital
Structure
Outstanding Debt To Be Refinanced; $1 Billion Share Repurchase To
Commence Following Close of Transaction
On-Going Royal... |
|
12 February 2013
Elan Announces Filing of Annual Report on Form 20-F for Year Ended December 31, 2012| DUBLIN--(BUSINESS WIRE)--Feb. 12, 2013--
Elan Corporation, plc (NYSE: ELN) today announced the filing of its
Annual Report on Form 20-F for the fiscal year ended December 31, 2012.
The Form 20-F is available on Elan's website at http://www.elan.com.
Elan will provide to all holders of Elan securities, upon request and
free of charge, a hard copy of our complete audited financial statements
included in our Form 20-F.
About Elan Corporat... |
|
06 February 2013
Elan Announces Restructuring of Tysabri Collaboration with Biogen Idec|
Migrate From The Current 50:50 Business Collaboration To A New
Structure
Upfront Payment Of $3.25 Billion Plus Double Digit Tiered Royalty
For Complete Asset
Tax Efficient Transaction
Simplified Structure Enables Improved Alignment Of Therapy To
Patients
Provides Capital And Long Term Cash Flow For Investment, Growth And
Business Diversificatio... |
|
06 February 2013
Elan Reports Fourth Quarter and Full-Year 2012 Financial Results|
Full Year 2012 guidance met; Pro-forma Revenues up 13%; Adjusted
EBITDA up 31%
Capital structure strengthened through debt refinancing and
Alkermes shares sale
Tysabri transaction creates greater financial flexibility to grow
shareholder value - $3.25 billion upfront plus double-digit future
royalties
DUBLIN--(BUSINESS WIRE)--Feb. 6, 2013--
Elan Corporation, plc today... |
|
31 January 2013
Elan Sells Its Remaining Stake in Alkermes| DUBLIN--(BUSINESS WIRE)--Jan. 31, 2013--
Elan Corporation, plc (“Elan”) (NYSE: ELN) announced that, following the
close of trading today, Elan, through its wholly-owned subsidiary, Elan
Science Three Limited, agreed to sell, on customary terms, all of its
remaining 7,750,000 ordinary shares of Alkermes plc (“Alkermes”)
(NASDAQ: ALKS) through Jefferies & Company, Inc. pursuant to Rule 144
under the U.S. Securities Act of 1933. The sale is expected... |
|
23 January 2013
Elan Announces Webcast of Fourth Quarter and Full-Year 2012 Financial Results| DUBLIN--(BUSINESS WIRE)--Jan. 23, 2013--
Elan Corporation, plc (NYSE: ELN) announced today that it will host a
conference call on Wednesday, February 6, 2013 at 8:30 a.m. Eastern
Standard Time (EST), 1:30 p.m. Greenwich Mean Time (GMT) with the
investment community to discuss Elan’s fourth quarter and full-year 2012
financial results, which will be released before the European and U.S.
financial markets open.
Live audio of the conferen... |
|
16 January 2013
Biogen Idec and Elan Submit Applications for First-Line Use of TYSABRI in Anti-JCV Antibody Negative Patients with MS|
- Marketing Applications Supported by Risk Stratification Data -
WESTON, Mass. & DUBLIN--(BUSINESS WIRE)--Jan. 16, 2013--
Today Biogen
Idec (NASDAQ: BIIB) and Elan
Corporation, plc (NYSE: ELN) announced that they have submitted
applications to the U.S. Food and Drug Administration (FDA) and European
Medicines Agency (EMA) requesting updates to the TYSABRI®
(natalizumab) labels. The applications request an expanded indication
... |
|
RSS Feeds | 
E-mail Alerts | 
Contact IR